Effects of Gelesis200 on Appetite Parameters, Food Intake, and Glycemic Control in Overweight or Obese Prediabetic Subjects: A Sub-Study of LIGHT-UP

Inclusion Criteria: * Male or female ambulatory subjects * Age ≥22 years and 65 years * Body Mass Index (BMI) ≥27 and ≤40 kilogram (kg)/meter (M)2 with body weight \<120 kg * Prediabetic subjects with FPG ≥100 milligram (mg)/deciliter (dL) and \<126 mg/dL \[≥5.6 millimole (mmol)/liter (L) and \<7.0 mmol/L\] at both Screening Visits with HbA1c ≤6.4% \[≤46 mmol/mole (mol)\] \[if only one (1) value is within this range, the other value should not be ≥126 mg/dL (≥7.0 mmol/L) and HbA1c should be ≥5.7% (≥39 mmol/mol) and ≤6.4% (≤46 mmol/mol)\], untreated diabetic subjects with FPG ≤ 200 mg/dL (≤ 11.2 mmol/L) at both Screening Visits and either FPG ≥126 mg/dL (≥7.0 mmol/L) at both Screening Visits or HbA1c ≥6.5% (≥48 mmol/mol) if FPG is \<126 mg/dL (\<7.0 mmol/L) at one (1) or both Screening Visits, or metformin-treated diabetic subjects with FPG ≥70 mg/dL and ≤270 mg/dL (≥3.9 mmol/L and ≤15.1 mmol/L) at both Screening Visits * Fasting serum insulin \<24 microunit (\[Symbol\]U)/milliliter (mL) at both Screening Visits in prediabetic subjects * Ability to follow verbal and written instructions * Consent obtained via signed ICF Exclusion Criteria: * Pregnancy \[or positive serum or urine pregnancy test(s) in females of childbearing potential\] * Absence of medically approved contraception in females of childbearing potential \[exempli gratia (e.g.), hysterectomy, oral contraceptive medications, intrauterine device combined with a barrier method, two (2) combined barrier methods such as diaphragm and condom or spermicide, or condom and spermicide; bilateral tubal ligation and vasectomy are acceptable contraceptive methods when combined with another single method from above\] * History of allergic reaction to carboxymethylcellulose (CMC), citric acid, maltodextrin, gelatin, or titanium dioxide * Participation in a weight loss study within the past twelve (12) months * Administration of Gelesis100 or Gelesis200 in a previous study * Administration of investigational products within one (1) month prior to Screening Visit * Smoking cessation within six (6) months prior to Screening Visit or considering smoking cessation during the study * Anticipated surgical intervention during the study period * Known Type 1 Diabetes * History of eating disorders including binge eating (except for mild binge eating) or emesis ≥2/week from any cause * Weight change \>3% within three (3) months prior to and during the Screening period * Supine systolic blood pressure (SBP) \>160 millimeters of mercury (mmHg) and/or supine diastolic blood pressure (DBP) \>95 mmHg * Angina, coronary bypass, or myocardial infarction within six (6) months prior to Screening Visit * History of swallowing disorders * Esophageal anatomic abnormalities (e.g., webs, diverticuli, rings) * History of gastroesophageal reflux disease * History of gastric or duodenal ulcer * History of gastroparesis (e.g., chronic nausea, vomiting ≥2 occurrences per week, heartburn, etc.) * History of gastric bypass or any other gastric surgery * History of small bowel resection (except if related to appendectomy) * History of intestinal stricture (e.g., Crohn's disease) * History of intestinal obstruction or high risk of intestinal obstruction, including suspected small bowel adhesions * History of abdominal radiation treatment * History of pancreatitis within the past 12 months * History of malabsorption * Laxative users, except those on stable doses within one (1) month prior to Screening Visit * History of hepatitis B or C * History of human immunodeficiency virus (HIV) * History of cancer within the past five (5) years (except adequately-treated localized basal cell skin cancer or in situ uterine cervical cancer) * Any other clinically significant disease interfering with the assessments of Gelesis200 (e.g., disease requiring corrective treatment, potentially leading to study discontinuation) * Abnormal serum thyroid-stimulating hormone (TSH) * HbA1c \>8.5% (\>69 mmol/mol) * Serum low-density lipoprotein (LDL) cholesterol -≥160 mg/dL (≥4.15 mmol/L) * Serum triglycerides ≥350 mg/dL (≥3.96 mmol/L) * Positive test for drugs of abuse in the urine * Any relevant biochemical abnormality interfering with the assessments of Gelesis200 * Anti-obesity medications (including herbal preparations) within one (1) month prior to * Screening Visit * Systemic corticosteroids within one (1) month prior to Screening Visit * Thyroid hormones or preparations within one (1) month prior to Screening Visit \[except stable dose of replacement therapy for at least two (2) months\] * TSH suppression therapy for thyroid cancer * Estrogen within one (1) month prior to Screening Visit \[except stable dose of replacement therapy or contraceptives for at least one (1) month\] * Any other medication known to cause weight loss or weight gain within one (1) month prior to Screening Visit * Antidiabetic medications within one (1) month prior to Screening Visit \[except stable doses of metformin for at least one (1) month in subjects with Type 2 Diabetes\] * Change in medications treating hypertension within one (1) month prior to Screening Visit * Change in medications treating dyslipidemia within one (1) month prior to Screening Visit * Anticipated requirement for use of prohibited concomitant medications * Any other condition that, in the opinion of the Investigator or Sponsor, would interfere with the subject's ability to participate in the study